Cutting out the middleman: Genentech jumps on direct-to-patient bandwagon with flu drug Xofluza

Genentech joins other major pharmaceutical companies in offering a popular flu medication directly to consumers, potentially ...
Fierce Pharma

Genentech preps for flu season with DTC program offering discounted Xofluza

The discounted access to Xofluza comes as the U.S. flu season begins. Genentech pointed to CDC data showing that last year’s ...

Oral drug combination extends progression-free survival in advanced ER-positive breast cancer

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free ...
Fierce Pharma

Amgen, AZ's Tezspire gains 2nd FDA nod, upping the ante in its battle with Dupixent

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...
Fierce Healthcare

Serve You Rx, Waltz Health partnership drives 90% biosimilar conversation rate

Waltz Connect is built on AI-enabled prescription routing technology as well as a specialty marketplace that encourages ...
The Bakersfield Californian

Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the company’s first Direct-to-Patient (DTP) program. This program, which supports President Trump’s goal to make ...